HistoSonics is a medical device company specializing in the development of non-invasive tissue destruction technologies based on focused ultrasound. Its device, the Edison System, represents the world’s first automated sonic beam therapy platform leveraging the Histotripsy mechanism for the treatment of liver tumors. HistoSonics has received FDA clearance for the destruction of liver tumors, including unresectable tumors, and is actively expanding its clinical portfolio toward renal, pancreatic, and prostatic indications.
